Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eque-cel in Relapsed/Refractory Multiple Myeloma
NCT07510100Phase 2Not yet recruiting
- Sponsor
- Reindeer Biotech
- Start
- May 2026
- Primary completion
- Aug 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of equecabtagene autoleucel in multiple myeloma (MM), sponsored by Reindeer Biotech. Planned start May 2026; status: not yet recruiting.
02
Drugs
equecabtagene autoleucel
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07510100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07510100.